Skip to main content
Fig. 1 | The Journal of Headache and Pain

Fig. 1

From: The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the Prostaglandin E2 human model of headache

Fig. 1

Median (filled square) and individual headache scores on a verbal rating scale (VRS) on placebo compared to either pretreatment day with BGC20-1531. The median peak immediate headache score was 2 at T20 on placebo day, 1.5 at T30 on BGC20-1531 200 mg day, and 1 at T20 on BGC20-1531 400 mg day. No difference between AUC headache score on placebo and either BGC20-1531 pretreatment was found (Wilcoxon signed ranks test)

Back to article page